Q 122

Drug Profile

Q 122

Alternative Names: MSX-122; Q-122

Latest Information Update: 06 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emory University; University of Queensland
  • Developer Altiris Therapeutics; QUE Oncology
  • Class Anti-inflammatories; Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hot flashes

Highest Development Phases

  • Phase I Hot flashes
  • Discontinued Solid tumours

Most Recent Events

  • 03 Nov 2014 Phase-I clinical trials in Hot flashes in USA (PO) before November 2014
  • 03 Nov 2014 Q 122 is available for licensing as of 03 Nov 2014. http://www.queoncology.com
  • 16 Apr 2008 Pharmacodynamics, pharmacokinetics and adverse events data from Preclinical trials in Solid tumours presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top